

Publishable Summary

This quarterly report aims at providing detailed information on the progress of the AMYPAD Diagnostic and Patient Management study with a specific focus on the progress achieved during the third quarter of 2019. The report shows the increase in the recruitment of patients in the active sites as well as the work made to include more sites in the study.

During this review, the Sponsor demonstrates that the initially targeted eight sites are now approved and active for patients' recruitment.

With the addition of Lausanne (CHUV) and Stockholm (KI) to the already active sites, the recruitment expectations are in line with the recruitment objectives. Lausanne already included patients and Stockholm team is just about to recruit their first patient. Recently thought to be a potential additional site, Imperial College London (ICL) inclusion couldn't be pursued considering the time constraints to obtain a three parties legal agreement.

During this third quarter of 2019, the 50% enrolment milestone has been reached on August, 28th, 2019. Currently, 489 patients are enrolled in AMYPAD DPMS and undergoing the different visits.

In parallel, scanning activities have also progressed, with over 290 scans performed in the different sites. The tracer balance between Vizamyl and Neuraceq is aligned with expectations (45% vs. 55% respectively)

In the meantime, the DPMS team has grown with a dedicated data manager currently working with sites and on the clinical database to ensure the quality of the data collected, allowing the first analysis to be performed.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.